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In recent years, high performance computing (HPC) has begun to revolutionize 
the architecture of software and servers to meet the ever-increasing demand for speed 
& efficiency.  One of the ways this change is manifesting is the adoption of graphics 
processor units (GPUs).  Used correctly, GPUS can increase throughput and decrease 
compute time for certain computational problems.  Bioinformatics, an HPC dependent 
discipline, is no exception.  As bioinformatics continues advance clinical care by 
sequencing patient’s DNA and RNA for diagnosis of diseases, there is an ever-increasing 
demand for faster data processing to improve clinical sequencing turnaround time.    
 Parabricks, a GPU enabled bioinformatics software is one of the leaders in ‘lifting 
over’ common CPU bioinformatics tools to GPU architectures.  In the present study, 
bioinformatics pipelines built with Parabricks GPU enabled software are compared with 
standard CPU bioinformatics software.  Pipeline results and run performance 
comparisons are performed to show the impact this technology change can have for a 
medium sized computational cluster.  
 The present study finds that Parabricks’ GPU workflows show a massive increase 
in overall efficiency by cutting overall run time by roughly 21x, cutting overall 
computational hours needed by 650x. Parabricks GPU workflows show a 99.5% variant 
call concordance rate when compared to clinically validated CPU workflows.  
Substitution of Parabricks GPU alignment into a clinically validated CPU based pipeline 
reduces the number of compute hours from 836 hours to 727 hours and returns the 
same results, showing CPU and GPU’s can be used together to reduce pipeline 
turnaround time & compute resource burden.  Overall, integration of GPUs into 
bioinformatic pipelines leads to massive reduction of turnaround time, reduction of 
computation times, and increased throughput, with little to no sacrifice in overall output 
quality.  The findings of this study show GPU based bioinformatic workflows, like 
Parabricks, could greatly improve whole genome sequencing accessibility for clinical use 
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The fields of bioinformatics and clinical genomics have grown rapidly with the 
rise of next generation sequencing and the subsequent increase in publicly available 
data and decrease in the cost to generate genomic data.  Despite the growth of the 
clinical genomics, clinical sequencing still faces challenges in becoming a routine 
diagnostic test, causing it to remain a last-ditch effort to end a diagnostic odyssey.  Of 
the major challenges facing whole genome sequencing (WGS), the high cost and long 
turnaround time (TAT), the time from test order through results reporting, remain the 
largest hurdles to making whole genome sequencing (WGS) a staple of diagnostic 
testing (Manolio, 2017).  While advances in sequencing technology and testing 
availability have improved clinical WGS TAT, bioinformatic computation and variant 
analysis remain a challenge due to the volume of data and amount of hands on time 
required by analysts (Miller, 2015).  Within this study, a new graphics processor unit 
(GPUs) based bioinformatics toolset called Parabricks is assessed against standard 
bioinformatics pipelines using central processing units (CPUs), showing drastic reduction 
of TAT with no sacrifice in clinical efficacy.    
Clinical Genomics 
Since the start of the Human Genome Project, integration of computer science 
into genetic sequencing has played a key role in the growth of genomics for research 






analysis have become more intertwined, the cost of sequencing has reduced drastically.  
Estimates published in 2018 show clinical whole exome sequencing (WES) ranges from 
$555 to $5,169 and clinical whole genome sequencing (WGS) from $1,906 to $24,810 
(Schwarze, 2018).  While current WES and WGS costs are still prohibitive for most 
patients, the current price is a drastic reduction from the 2.7 billion dollar price tag of 
the first human genome in 2003 (National Institute of Health, n.d.).  The decrease in 
sequencing cost is driven by technological innovations allowing for high throughput 
sequencing of many samples in parallel called Next Generation Sequencing (NGS) 
(Schwarze, 2018).  As the cost of sequencing continues decreases, NGS has continually 
showed its ability to transforming the diagnostic methods for finding causes of both rare 
& common mendelian diseases, as well as providing accurate diagnosis and targeted 
treatment of cancer (Cirulli, 2010) (Willig, 2015).  
Despite the price decrease of WES and WGS testing in recent years, the world of 
clinical genomics still faces challenges.  The largest challenges remain turnaround time 
(TAT), variant interpretation and data management (Rossen, 2018) (Meienberg, 2016).  
A single patient’s WGS data can result in hundreds of gigabytes of data and can take 
thousands of hours of server time (Muir, 2016).  In recent years, the growth of cloud 
computing and storage has decreased the cost of maintaining servers and have made it 
easier to scale up workflows, but has not done much to increase the use of WGS over 
using smaller exome and genome panels (Muir, 2016). At present, it remains much more 
effective for clinicians to order smaller gene panels and WES than WGS due to the lower 






patients due to their lower cost, as they require less sequencing, less computation and 
less hands-on analytical time.   
Despite the drawbacks of high data volume, long compute time, and costly 
hands variant curation requirements, there is little disagreement that WGS is a highly 
effective method for clinical diagnostics.  Many clinicians argue that WGS should be a 
front line defense for neonatal crises and should be utilized in the management of acute 
medical care (Miller, 2015) (Saunders, 2012) (Manolio, 2017).  WGS has been shown to 
help in these scenarios by assisting in diagnosing rare and new diseases, diagnosing 
cases with atypical presentation and can help in cases where standard treatments are 
ineffective (Miller, 2015). WGS findings additionally assist clinicians in managing and 
treating diseases by giving insights into a disease’s etiology, offering clinicians insights 
into treatment as opposed to long term management of symptoms (Clark, 2019).  WGS 
sequencing also has the ability to show clinicians when irremediable damage is done to 
the genome, allowing them to begin palliative care knowing they have done all they can 
for their patients without prolonging suffering (Willig, 2015). 
WGS additionally provides methodological benefit by superior data to target 
sequencing methodologies such sequencing by exome capture or PCR amplification.  
WGS’ indiscriminate method of genome surveillance and variant detection can lead to 
detection of previously unknown pathogenic disease origins (Lionel, 2018).  Whole 
genome sequencing also has better resolution for calling copy number variants (CNVs), 






breakpoints and by giving better resolution of large genomic events (Lionel, 2018).  By 
contrast, exome and targeted panels have difficulty detecting CNVs, due to the finite 
targets, and limited resolution (Zhao, 2013).  Perhaps counterintuitively, a negative 
result from a WGS test is more significant result than a negative targeted panel.  This 
means that a negative result from WGS testing is less likely to leave clinicians and 
patients wondering if they need to order a more comprehensive or advanced test. 
Another scenario in which WGS sequencing has utility is neonatal crisis, where 
any of an estimated 500-1000 different genes can drive newborns to rapidly deteriorate 
(Kingsmore, 2012).  Neonatal crises account for around 20% of newborn deaths in the 
US and up to 18% of newborn hospitalizations (Kingsmore, 2012).  Many these 
syndromes and metabolic conditions are reversible and preventable if detected early 
and treatment is administered within a reasonable amount of time.  Two such examples 
of preventable & manageable diseases include phenylketonuria (PKU) and congenital 
hypothyroidism which effect 1 in 10,000 and 1 in 2,000 newborns respectively 
(Kingsmore, 2012).  While the cost of WGS testing might seem cost prohibitive for 
routine use in diagnoses of rare diseases, the cost of testing is much more reasonable 
when compared to a daily price tag of $3,500+ in the Neonatal Intensive Care Unit 
(NICU) (Muraskas & Parsi, 2008).  However, current WGS turnaround times of 1-2 
months remain woefully insufficient to make an impact in many cases (Thiffault, 2019).  
The speed of WGS sequencing and analysis continues to prevent the power of the 







Central processing units (CPUs) are the standard calculator that perform 
computations within a computer.  Throughout the rise of computers, the driving force 
increasing computer performance and software speed was the advancement of CPU 
speed.  This concept has termed “Moore’s Law”, named after the author of the 
landmark 1965 paper, posits, “The complexity for minimum component costs has 
increased at a rate of roughly a factor of two per year” (Moore, 1998).   This phrase was 
come to be understood that computational power of standard CPUs would double every 
12-18 months and has been remarkably accurate over the last half century.  
 More recently, Moore’s law has run out of runway.  While transistors per chip 
continues to double every 12-18 months, speeds of processors have reached a plateau 
(Waldrop 2016) (Figure 1).  The driver of this plateau is that CPU hardware is 
approaching fundamental physical limitations, in which speeds cannot improve the 
speed without employing super cooling or involving massive power consumption 
(Markov, 2014). The consequences of this phenomenon are far reaching.  Previously, if a 
developer wrote a piece of software, all they would need to do to make it go faster is 
wait for a faster generation of processers to come out.  Now, to achieve greater 
performance developers need to get more creative in their coding or must look to new 









One such architectural solution is the multi-core processor, in which multiple 
processors work in sync to accomplish tasks. Provided the software used can operate 
with multiple CPUs, this improvement allows for large tasks to be spread across many 
CPUs to accomplish the task sooner.  While multicore processing can increase the 
number of computations that can be done in a given amount of time, it has some 
notable drawbacks.  One of the most important predictors of a computational task’s 
speed increase is parallelizability, termed “f”.   
Each unique combination of computational task, operating system and hardware 
combine to create a unique f value.  In general, each additional CPU assigned to a task 
increases the speed but depending on the parallelizability of the task (f), there is a 
Figure 1: A plot showing the relationship between clock speed and transistors per chip over the last 50 






diminishing return in overall CPU efficiency (Figure 2).  This diminishing return on CPU 
resource investment is known as Ahmdal’s law (Sun, 2010).  This means that efficiency 
and fold speed up of adding more CPUs to speed up a computation is gated by f.  As f 
decreases, so does the return on investment for each CPU added to a computation.  As 
bioinformaticians and software engineers look to increase the speed of WGS pipelines, 
they are forced to re-design how their code functions, break tasks into many parts, or 
look to other computational architecture in order to increase the parallelizability.  
 
Figure 2: A representation of the relationship between the parallelizability (f) of a 
computational job, the number of CPU cores assigned to it, and the fold speedup of the 
job’s completion (Sun, 2010)  









Graphics processor units (GPUs) represent another of the solution to HPC 
throughput.  GPUs initial purpose were specifically for high resolution screens- where 






second.  GPUs are rapidly being adopted into HPC workflows as they can outperform 
CPUs for tasks that require many simple computations at once (Nickolls, 2010).  By using 
code specifically designed for GPUs, GPU architectures can work in synergy with CPUs to 
massively speed up computational jobs.  While GPUs can represent a large performance 
upgrade, the drawback is increased difficulty in code design and great difficulty involved 
in troubleshooting.   
Bioinformatics as a discipline is extremely familiar with high complexity HPC 
problems.  For example, in alignment of a single sequencing ‘read’ consisting of a string 
of 200-300 As, Ts, Cs, and Gs to the human genome, must compute the ‘optimal’ 
placement of the read into to a genome 3.2 billion bases in length.  This matrix 
multiplication must be performed one or more times for each sequencing read in a 
genome.  A standard clinical WGS sequencing can produce upwards of 500 million reads.  
Meaning this N x M computation could be performed 500 million times to create a 
single base alignment map file (BAM file).  Even divided across many different CPU 
processors, this computation can take hours or days to complete.  Fortunately, genome 
alignments matrix multiplication is what many in the computer science industry call a 
“ridiculously parallel” problem, meaning no single computation is dependent on any 
other.  This makes alignment and many bioinformatic tasks perfectly suited to GPU 
workflows.  Until now, one of the greatest drawbacks to implementing GPU workflows is 
the difficulty of troubleshooting errors when they arise, and the difficulty of 






GATK & Parabricks Bioinformatics Tool Suites 
The Genome Analysis Tool Kit (GATK) is a suite of open sourced highly versatile 
Java based bioinformatics tools from the Broad Institute is an (Van der Auwera, 2013).  
GATK has tools ranging from raw read trimming to de novo genome assembly to 
alignment of raw reads to reference genomes to somatic & germline variant calling 
(Rimmer, 2014) (Van der Auwera, 2013).  GATK’s wide user base and vast 
documentation makes is a favorite of bioinformaticians.  While extremely reliable, 
GATK’s major drawback is currently that it is CPU based and its distributed SPARK 
architecture has been for development use only since 2017. 
Parabricks, now a product of NVIDIA, is a commercially available tool which 
converts GATK based functions and algorithms their native CPU architecture to a GPU 
architecture (Figure 3).  Parabricks functions by keeping the underlying GATK tools the 
same, but adapts the most critical & parallelizable algorithms over to GPU enabled 
CUDA code (NVIDIA (Parabricks), 2020) (NVIDIA (CUDA), 2020).  The Parabricks software 
 







is specifically written for the NVIDIA DGX-1, a single unit that contains 8 separate GPUs.  
Parabricks boasts that their software can cut GATK pipeline turnaround times (TAT) by 
40-60 times (NVIDIA (Parabricks), 2020).  If true, this reduction in TAT poses a 
breakthrough in bioinformatics that has the ability to increase WGS throughput, cut 
WGS TAT and have a positive impact for patients and clinicians alike.  
Study Objective 
The goal of this study is to test Parabricks GPU enabled bioinformatic workflows 
and tools against clinically validated CPU bioinformatic workflows for efficacy of clinical 
whole genome sequencing (WGS).  Evaluations for each pipeline include overall 
bioinformatic workflow turnaround time (TAT), genome alignment TAT and 
performance assessment of variant calling on National Institute of Standards and 
Technology (NIST) Gold Standard Genome in a Bottle sample NA12878.  Parabricks 
claims to reduce pipeline TAT by 40x to 60x over standard GATK pipelines with no 
sacrifice in output quality.  If their claims are true, Parabricks has ability to revolutionize 
whole genome sequencing by reducing WGS TAT and increasing the clinical utility of 






METHODS & MATERIALS 
Sequencing Data 
The comparisons performed within this document were performed on 3 de-
identified human samples from DNA. WGS-High Coverage (WGS-HC), a deeply 
sequenced genome sample with about 150x coverage of the genome, WGS-Normal 
Coverage (WGS-NC), 55x sequencing depth, and the Genome in a Bottle (GIAB) NA12878 
national reference sample purified from cell line (National Institute of Standards and 
Technology, 2020).  All samples had library preparation with Illumina’s TruSeq Nano 
Whole Genome preparation per manufacturer specifications (Illumina, 2020).  All 
samples were sequenced bi-directionally with 2x150 reads on the same Illumina 
NovaSeq using an SP flowcell.  Raw read data was prepared using of BCL2Fastq2 v2.20 
and was stored in fastq.gz format (Illumina, 2019).    
Pipelines Tested 
 3 Separate pipelines were tested within this study all aligning to Genome 
Reference Consortium Human Build 37 (GRCh37) genome (Church, 2011).  The three 
pipelines tested in this study were: 1) ‘Clinically Validated CPU’ based, Whole Genome 
Sequencing (WGS) pipeline based on GATK  2) ‘Parabricks Rapid’, a germline pipeline for 
WGS built only on the Parabricks tool suite, 3) ‘Parabricks hybrid’ pipeline, a 
combination of pipeline 1 and 2, in which the alignment is performed by Parabricks GPU 
BWA alignment algorithm. All other tasks are performed by the standard CPU Pipeline.  






Table 1: Non-Quality control steps and software performing them in CPU, Hybrid and GPU 
pipelines tested within this document. 
Pipeline Step CPU Pipeline Hybrid Pipeline 
Parabricks GPU 
pipeline 





































BCFtools Norm BCFtools Norm NA 
 
All GATK applications used within this study were performed on GATK version 
4.1.2.0 (DROAZEN, 2019).  Parabricks runs were performed on v2.4.6, using GATK 
functions were lifted over from GATK v4.1.2.0.  
Computation Environment 
CPU based computations were performed on a 15 node HPC cluster consisting  
340 Intel(R) Xeon(R) Gold 6154 3.00GHz CPUs, each node containing 6 TB of ddr3 
memory.  GPU computations are performed on a Nvidia DGX-One with 2-24 core 2x 
Xeon Gold 8268 CPUs, and 8 NVIDIA Tesla P100 GPUs, and 512GB DDR4-2133 + 128GB 






GPU compute jobs were managed by Torque v4.2.6 (Adaptive Computing, 2013) .  GPU 
computations were performed using CUDA v 10.1 (NVIDIA (CUDA), 2020).   
Alignment Benchmarking 
 As genomic alignment tends to be the rate limiting step of most genomic 
pipelines, an initial benchmarking of Parabricks Alignment + MarkDuplicates (BWA) 
algorithm was performed using 2, 4 & 8 of the dedicated GPUs each in quadruplicate.  
During the 2 and 4 GPU Parabricks alignment + mark duplicates assessments, all DGX 
GPUs not under assessment were assigned alignment jobs to simulate uniform input / 
output volume across the entire unit.  Using the same sample input data, A GATK BWA-
MEM alignment + Mark Duplicates was performed in quadruplicate with 8 CPUs 
dedicated using GATK best practices (GATK (Best Practices), 2020).  Turnaround times of 
2, 4 and 8 GPU Parabricks alignments were compared to CPU alignments. 
Pipeline TAT Benchmarking 
To test the turnaround time of the CPU, GPU and hybrid pipelines, each pipeline 
was run from fastq files using sample WGS-HC (150x genome coverage), WGS-NC (55x 
genome coverage), aligning to GRCh37.  Each pipeline was run in duplicate and the 
turnaround time was averaged.  Turnaround time was measured from pipeline start to 
completion.   
A second analysis was performed on the same pipeline runs to compare the 
Hybrid and CPU pipelines.  The TAT of each step of the critical path, or longest path of 






GATK CPU alignment when all other steps remain the same.  Job statistics were 
obtained from the Torque scheduler logs.  
Variant Calling Performance 
The variant calling output for all three pipelines were assessed using NIST GIAB 
sample NA12878 was used to assess variant calling performance of each pipeline.  The 
published NIST NA12878 ‘High Confidence’ variant call set was used to assess each 
pipeline’s output VCF file (Zook J. M., 2019).  The bed file for NA12878 high confidence 
variant call files was bed intersected over all pipeline VCF files (Quinlan, 2010).  The VCF 
files for each pipeline, restricted to the high confidence regions, were then compared to 
the NIST published high confidence variant calls from sample NA12878 using VCFtools’ 
vcf-compare (Danecek, 2011).  The definitions of true positives, true negatives, false 
positives and false negatives shown in Table 2 were used to assess performance. 
 
Table 2: Definitions of performance metrics as used to assess GPU, CPU and hybrid 
pipeline clinical efficacy. 
Term Definition 
True Positive (TP) 
Matching reference and alternate allele between pipeline 
output and published NA12878 high confidence call set  
True Negative (TN) 
Site within the NA12878 high confidence region bedfile, but 
with no variant calls in both pipeline VCF and NA12878 high 
confidence variant call file 
False Positive (FP) 
Site with variant call present in pipeline VCF output, but no 
matching call in the NA12878 high confidence variant call 
file 
False Negative (FN) 
Site with no call in pipeline results VCF and a variant present 
in NA12878 high confidence variant call  
Sensitivity TP / (TP + FN) 








TP / (TP + FP) 
Negative Predictive 
value (NPV) 









CPU Alignment vs GPU Alignment 
To assess the efficiency of alignment by Parabricks, the same fastq files were run 
on the GATK based CPU pipeline, as well as the Parabricks pipeline, using 2, 4, and 8 
dedicated GPUs to align and mark duplicate reads (Figure 4).  All CPU alignments were 
performed given 8 CPUs.  All alignments on the CPU and GPU pipelines were performed 
using the same GATK alignment parameters.   
 
Figure 4: Alignment + Mark Duplicates comparison between Parabricks GPU alignment 


























Comparing run times of the CPU and GPU architecture shows a stark difference 
the overall time it takes for the genomic alignment and duplication marking to 
complete.  Running with only two dedicate GPUs, the alignment and mark duplicates 
together runs twice as fast as the CPU duplicate marking alone.  Comparing GPU 
turnaround time of 150x depth WGS-High Coverage (WGS-HC) to the 55x depth WGS-
Normal Coverage (WGS-NC) shows that the GPU alignment time is linear to the sample’s 
sequencing depth 
Further comparison of the CPU and GPU Alignment + Mark Duplicates speed 
shows increase was highly correlated to the number of GPUs dedicated to the job.  Tests 
were run with 2, 4, 8 GPUs dedicated to the alignment job showed an 8x, 16x, 28x speed 
increase in alignment respectively (Figure 5).  Showing that the GPU architecture does 



















Figure 5: Fold speed increase of 2, 4, 8 GPUs dedicated to alignment of compared to standard 






Turnaround Time Comparison: GPU vs CPU Pipeline 
To assess full pipeline turnaround time, all 3 pipelines were run on WGS-HC and 
WGS-NC samples.  The TAT is compared below to show TAT from job submission 
through completion for (Figure 6).  
 
Figure 6: Comparison of TAT of GPU, CPU and hybrid pipeline, for NGS-HC and NGS-NC 
samples 
 
The GPU pipeline speeds up the fastq to VCF TAT by about 25x when compared 






Turnaround Time Comparison: Hybrid Pipeline vs CPU Pipeline 
A hybrid pipeline was created by combining the Clinical CPU pipeline and 
Parabricks offloads alignment, mark duplicates, and bam sorting, 3 of the longest tasks 
in the Clinical CPU Pipeline.  The two pipelines were run on the WGS-NC and WGS-HC 
samples.  A comparison was performed of the critical path steps – or the steps that are 
dependent on a prior step before they can start (Figure 7).  
 
 
WGS-NC Hybrid WGS-NC CPU WGS-HC CPU 
Figure 7: Compute hours of the longest critical steps between CPU and Hybrid pipelines, 








For the CPU pipeline, the alignment and mark duplicates took more than 75% of 
the compute time required to complete the critical steps of the pipeline.  During this 
time, the resources dedicated to those tasks are both unable to be used by other tasks, 
and other essential processes in the pipeline cannot proceed because they are 
dependent on the aligned, sorted bam file.  In the Hybrid pipeline, the alignment and 
duplicates complete 25-27 fold faster, allowing for all of the downstream tasks 
dependent on the completion of alignment and mark duplicate steps to complete to 
start hours sooner.  The hybrid pipeline completed overall 5 times faster than the CPU 
pipeline did alone.  
Pipeline Variant Calling Efficacy 
NA12878, the NIST reference sample, was run from fastq on the clinically 
validated CPU pipeline, GPU Rapid pipeline and the Hybrid pipeline.  The resulting 
variant call files were bed intersected using Bedtools with the NIST published high 
confidence (HC) regions bed file, where many sequencing technologies were employed 
to create a high confidence consensus VCF file for SNPs and small INDELs (Zook J. M., 
2019) (Quinlan, 2010). The high confidence region consists of 2,575,632,881 bases.  
Variants within each pipeline’s ‘high confidence’ VCF file was compared to the published 
high confidence variant call set using VCFTools’ VCF-compare function (Danecek, 2011).   
Variant calls from the 3 pipelines were filtered using BCFtools to only include variants 
greater than 8x depth and QUAL scores greater than 20, no other filters were used in 






Table 3: Variant comparison between NIST NA12878 High Confidence variants and 
assessed pipeline VCF outputs in the same regions. 









Clinical CPU pipeline 3,577,524 66,604 119,070 2,571,869,683 
Hybrid (GPU align 
only) 
3,577,532 67,597 118,950 2,571,868,802 
Rapid (GPU) 3,675,949 67,419 86,782 2,571,802,731 
 
Variant calling comparisons from all three pipelines to the NIST HC call set 
showed 95.25% variant concordance for the Clinical CPU pipeline & Hybrid pipelines, 
and 97.88% concordance for the GPU pipeline (Table 4).  The hybrid pipeline and CPU 
pipeline only had 8 different variants calls from one another, all at sites with less than 
eight total reads.  While the Rapid GPU pipeline had 98,417 and 98,425 more calls 
matching the NIST High confidence variant call set, than the Clinical CPU and Hybrid CPU 
pipeline, respectively. Performance metrics were calculated for the three pipelines to 
show the overall efficacy of variant calling between the three pipelines (Table 4).  
 
Table 4: Performance metrics showing the sensitivity, specificity, positive predictive 
values and negative predictive values of all three pipelines as compared to the NIST High 








Clinical CPU pipeline 0.96779 0.99997 0.98172 0.99995 
Hybrid (GPU align 
only) 
0.96782 0.99997 0.98146 0.99995 







All three pipelines return similar performance results, however, the GPU based 
Rapid pipeline displayed a slightly higher sensitivity.  All three pipelines show high 
quality sensitivity and positive predictive value and superb specificity and negative 
predictive value (Table 4).    
An analysis of the discordant variants was performed to understand the 
differences between each pipeline output.  VCF output differences between the GPU 
pipeline and the Hybrid pipeline were largely due to differences in their handling of 
multiple nucleotide polymorphism calling (MNPs) (Figure 8).   Functionally, the protein 
product of the calls between all 4 files shown in figure 8 remain the same as the variants 
are call as in-phase, meaning they occur on the same strand of DNA.  The difference is in 
the results format of the MNPs vs the SNPs is the format of the quality metrics produce 
by the variant caller.  SNPs each receive their own quality assessment, while MNPs have 
their quality data merged for the combined variant.
 
 
Figure 8: IGV Screenshot showing comparisons of NIST High Confidence Callset, VCF, GPU VCF, CPU VCF and Hybrid VCF files 
(top to bottom), showing the same nucleotide changes between sites, but with the Clinical and Hybrid pipelines joining the 




Turnaround Time and Efficiency 
Implementation of Parabricks GPU enabled bioinformatic tools displays a clear 
advantage for process turnaround time.  Two samples were selected for test runs: an 
average depth genome WGS-NC (~55x), and WGS-HC (~150x).  The genomes were run 
on the Parabricks germline pipeline with 8 GPUs dedicated and CPU pipeline with 8 
CPUs dedicated to assessing the turnaround time of the two alignments.  The results 
were then used to create estimations below were made for a standard 35x coverage 
genome. 35x TAT assumptions were made under the assumptions that CPU and GPU 
compute hours are linear to the sequencing depth, and compute hours in Table 5 are 
available.  
 
Table 5:  Estimated CPU/GPU core hours available per year in the cluster described in 
this experiment. 
CPU core hours avail per year 2,978,400 
GPU core hours avail per year 70,080 
  
This analysis estimates that a 35x coverage genome sample will require a total of 
836 CPU hours per genome.  Using the estimations in table 5, this means the CPU cluster 







Table 6:  Estimated number of genomes able to be processed annually by the CPU 




Based on the results of this experiment implementation of the hybrid pipeline, 
hence offloading the alignment to the GPU, would offload roughly 101.8 CPU hours per 
whole genome pipeline run.  Using the core hour estimations described in Table 5, we 
can estimate how many more genomes can be run annually before saturating the 
system (Table 7).  Simply adding Parabricks GPU alignment and Mark Duplicates into 
CPU pipeline, the cluster described in this document can process 456 (11.3%) more 
genomes through the pipeline, with faster turnaround time.   
 
Table 7: An estimate of the number of 35x depth genomes that could be run annually on 













(all pipeline steps 
excluding alignment, 











727.9 4.36 4,092 4,018 4,018 
  
Running the Parabricks Rapid pipeline alone, assuming 35x coverage and 100% 
up time, a single DGX GPU system could process 2,037 genomes in a year (Table 8).   
Assay 
CPU Hour estimation 
(hours/sample) 
Maximum 
throughput per year 







Table 8: An estimate of the number of 35x whole genome pipeline runs that could be 
run annually on the CPU and GPU cluster described within this document via the 
Parabricks alone. 
   
 
 
It is worth noting that the CPU and hybrid pipelines have more quality control 
steps built in than the GPU pipeline.  Steps including GATK DepthOfCoverage, 
calculation of coverage for all gene regions and variant quality checks are extremely 
important steps for quality control and quality assurance in any clinical workflow.  These 
steps ensure that all regions of the genome are accurately represented within the 
sample, helping analysts ensure that lack of variation is not confounded with lack of 
sequencing data.  The power of the hybrid pipeline is the shortened of alignment, the 
longest step in the pipeline, combined with the added QC performed by the pipeline.  
Shortening required alignment time allows for all other dependent tasks start 
processing sooner, allowing for more efficient distribution of downstream jobs 
throughout the rest of the pipeline.  In contrast, the clinical CPU workflow has a major 
bottleneck at the alignment step.  While the CPU alignment is occurring, all other 
downstream jobs are waiting for alignment to complete, leading to an imbalance of CPU 
demand towards the end of the pipeline. 
Given the speed of the GPU pipeline, another potential method for reducing 
overall WGS TAT is using Parabricks for both alignment and variant calling, then using 
GPU Core Hour 
estimation (hours) 
Maximum WGS 







slower CPU quality assessments while the clinical variant assessment of the resulting 
VCF begins. The prospect of this is extremely attractive, as it would allow a clinical to go 
from DNA to analysis within two days.  Allowing for one day on the sequencer, 2-5 hours 
for Parabricks to generate a VCF, and finally uploading to analysis software.  Meanwhile, 
QC steps performed on the BAM and VCF can occur simultaneously.  If any quality issues 
such as low coverage or low quality are found, clinical variant analysis can be halted, 
and sequencing can be repeated to improve quality. 
Variant Calling Efficacy 
A bioinformatic pipeline is only as useful as it is accurate. To ensure the pipelines 
tested herein produce accurate variant calls, whole genome sequencing of the NIST 
Gold Standard reference sample NA12878, was run on each pipeline (Zook J. M., 2019).  
The results for all pipelines showed a high degree of efficacy for use in a clinical setting.  
In comparison with the gold standard within the high confidence regions, the Clinically 
validated CPU pipeline showed the worst sensitivity and positive predictive value (PPV), 
at 96.78% and 98.17%, respectively.  The Hybrid pipeline showed slightly better 
sensitivity and PPV, at 96.78 and 98.15%, respectively.  The rapid pipeline showed by far 
the most robust sensitivity and PPV, at 97.69% and 98.19%, respectively.   
While all three pipelines show impressive results, it is notable that raw variant 
concordance can be slightly misleading.  As mentioned earlier, the Rapid pipeline has 
very little built in QC.  Figure 9 shows a single variant within a homopolymer repeat of 






reports a single mutation within the region, at GRCh37 locus chr15:20,024,978.  With 
the exception of the Rapid pipeline calling two separate A > T mutations, rather than a 
multiple nucleotide polymorphism (MNP) of AAA>TAT, all three pipelines report the 
same variants within this region.  Notably in Figure 9, the hybrid and CPU pipelines show 
called variants with the exception the variant at site chr15:20,024,978 being ‘grayed 
out’, due to low quality flags being triggered in the GATK Variant Filtration quality 
control step (GATK (Best Practices), 2020).  These low-quality variants are reported in 
the VCF and are discordant from the NIST HC variants, the low-quality flag in the ‘FILTER’ 
column allows for an analyst or automated filter set to easily pass over these variants. 
Despite having the highest raw sensitivity, specificity, PPV, and NPV, the Rapid GPU 
pipeline has no such variant filtering step, meaning any doubtful variants must be 
scrutinized more by genomic analyst.  Given the superior speed of the GPU pipeline, it is 
more than reasonable to add an additional variant QC step to the end of the pipeline to 




Figure 9: An IGV screenshot of a low complexity genomic region showing the High Confidence callset and all three pipeline 





 All three pipelines display the sensitivity, specificity, PPV and NPV that is 
required of a clinical pipeline.  The Rapid GPU pipeline shows great promise for clinical 
work, showing the ability to decrease bioinformatic workflow turnaround times.  This is 
especially useful in cases of neo-natal crises, or other emergent situations where an 
early detection/diagnosis of diseases could prevent irreversible damage (Kingsmore, 
2012).  In these cases, whole genome sequencing has become a first line of defense for 
clinicians unable to diagnose disease by conventional diagnostic methods (Bodian, 
2014).  The largest draw back for these cases is the turnaround time for genome 
sequencing and reporting – which can take upwards of a month.  Implementing the 
Rapid GPU pipeline in these scenarios offers a massive speed up and could save lives in 
the process. 
 One of the notable drawbacks of the Rapid GPU pipeline as outlined in this study 
is the lack of built in quality control and quality assurance steps.  While this is true, the 
data outputs from the Rapid pipeline are in standard bioinformatic formats can easily be 
picked up by CPU based quality control methods.  CPU quality control steps can be 
applied to Parabricks GPU outputs, as demonstrated within the hybrid pipeline.  In the 
cases of neonatal crisis, genomic analysis of variants could even begin immediately upon 
the completion of the Rapid GPU pipeline.  Slower, CPU quality control steps could be 
performed in parallel to the initial clinical analysis.  Once quality control steps complete, 
the results can be assessed accordingly.  Combinations of the CPU and GPU methods 




 GPU based workflows are rapidly transforming the landscape of many HPC 
processes, especially in fields dependent on getting results quickly.  Genomics and 
bioinformatics present a perfect application for using GPUs to speed up computational 
workflows due to their ‘ridiculously parallel’ nature.  This study shows that Parabricks 
and its suite of genomics tools provide massive speed boost to current state of the art 
clinical workflows, cutting the time from job submission to results by four to five-fold.  
Some additional work needs to be done to Parabricks add quality control steps into the 
germline workflow. The ‘Hybrid Pipeline’ discussed within this study presents a 
reasonable method to both reduce turnaround time and makes use of quality control 
features present within the CPU based pipeline by adding CPU tools such as GATK’s 
Variant filtration or VQSR (GATK (Best Practices), 2020).  
 Parabricks’ speed and throughput increase for WGS processing also may provide 
a roundabout solution to the massive data volume produced by WGS pipelines.  As 
Parabricks drastically reduces the compute time for creating and recreating genomic 
data, output data could be deleted after analysis and only the smaller, raw sequencing 
data files kept long term.  This method would result in a drastic reduction of overall 
clinical data burden on clinical labs.  By only keeping raw data and rapidly recreating 
results on request, clinical labs may be able to lower prices on WGS clinical tests and 






In the context of clinical care, the speed of Parabricks GPU bioinformatic tools 
has been shown to reduce overall WGS bioinformatic pipeline processing time by days.  
Coupled with innovative analysis methods, such as starting variant analysis as soon as 
variant call files are ready, the processes Parabricks facilitates could cut up to a week 
from overall TAT.  While seemingly minimal, the reduced turnaround time can save lives 
by diagnosing diseases and starting treatments or clinical trials sooner or assist clinicians 
and families in the decision to start palliative care sooner.  The reduction in TAT can 
reduce the overall cost of treatment for patients by providing them a personalized care 
plan which can shorten inpatient hospital stays.  Finally, quicker results can reduce 
stress for families and clinicians alike by providing the most comprehensive test possible 
in a shorter time frame.   
Parabricks exhibits clinical efficacy showing high sensitivity, specificity, PPV and 
NPV that is ready for use right out of the box.  While minimal quality control is included 
in its standard workflow, the Parabricks suite of tools provides configurable modules 
that can be included in combined CPU and GPU pipelines.  Used wisely, Parabricks and 
GPUs can bring whole genome sequencing closer to a routine clinical test, rather than a 
last-ditch effort.  
Future Studies 
Future work surrounding the use of Parabricks and GPUs should be centered 
around applying additional quality control mechanisms to Parabricks Rapid GPU 






GATK’s VQSR, or GATK’s Filter variants (GATK (Best Practices), 2020).  Resulting Rapid 
GPU filtered VCFs then can be more meaningfully compared to one another compared 
against the filtered VCFs from the Clinical CPU pipeline.  The resulting comparison would 
give additional weight to the clinical efficacy of the GPU pipeline.  Another useful quality 
control feature that could be added to the GPU pipeline are DepthOfCoverage and Bam 
Statistics by BamTools (Barnett, 2011).  These additional comparisons and quality 
control steps would add the necessary quality control to go live with WGS bioinformatic 
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